Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14α-demethylase at the homologous locus

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 10, 2008, Pages 3597-3603

  Parker, J E ^a   Merkamm, M ^b   Manning, N J ^c   Pompon, D ^b   Kelly, S L ^a   Kelly, D E ^a  

^a SWANSEA UNIVERSITY   (United Kingdom)

^b CENTRE DE GÉNÉTIQUE MOLÉCULAIRE   (France)

^c SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

14ALPHA METHYL ERGOSTA 8,24(28) DIEN 3BETA 6ALPHA DIOL; ANTIFUNGAL AGENT; CLOTRIMAZOLE; COMPLEMENTARY DNA; ECONAZOLE; ERGOSTEROL; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; PYRROLE DERIVATIVE; STEROL 14ALPHA DEMETHYLASE; UNCLASSIFIED DRUG; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG TARGETING; FUNGUS GROWTH; GENE EXPRESSION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SACCHAROMYCES CEREVISIAE; STRAIN IDENTIFICATION; YEAST;

ANTIFUNGAL AGENTS; AZOLES; BASE SEQUENCE; CYTOCHROME P-450 ENZYME SYSTEM; DNA, FUNGAL; DRUG RESISTANCE, FUNGAL; GENES, FUNGAL; HUMANS; MOLECULAR SEQUENCE DATA; RECOMBINANT PROTEINS; SACCHAROMYCES CEREVISIAE; SACCHAROMYCES CEREVISIAE PROTEINS; SPECIES SPECIFICITY;

EID: 54049121819     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00517-08     Document Type: Article

References (29)

1. Bammert, G. F., and J. M. Fostel. 2000. Genome-wide expression patterns in Saccharomyces cerevisiae: comparison of drug treatments and genetic alterations affecting biosynthesis of ergosterol. Antimicrob. Agents Chemother. 44:1255-1265.
2. Barchiesi, F., D. Arzeni, A. W. Fothergill, L. F. Di Francesco, F. Caselli, M. G. Rinaldi, and G. Scalise. 2000. In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens. Antimicrob. Agents Chemother. 44:226-229.
3. Bellamine, A., G. I. Lepesheva, and M. R. Waterman. 2004. Fluconazole binding and sterol demethylation in three CYP51 isoforms indicate differences in active site topology. J. Lipid Res. 45:2000-2007.
4. Collart, M. A., and S. Oliviero. 1993. Preparation of yeast RNA, unit 13.12 ed., vol. 2. Wiley, New York, NY.
5. Gothard, P., and T. R. Rogers. 2004. Voriconazole for serious fungal infections. Int. J. Clin. Prac. 58:74-80.
6. Gueldener, U., J. Heinisch, G. J. Koehler, D. Voss, and J. H. Hegemann. 2002. A second set of loxP marker cassettes for Cre-mediated multiple gene knockouts in budding yeast. Nucleic Acids Res. 30:e23.
7. Heeres, J., L. J. Backx, J. H. Mostmans, and J. Van Cutsem. 1979. Antimycotic imidazoles. Part 4. Synthesis and antifungal activity of ketoconazole, a new potent orally active broad-spectrum antifungal agent. J. Med. Chem. 22:1003-1005.
8. Kalb, V. F., C. W. Woods, T. G. Turi, C. R. Dey, T. R. Sutter, and J. C. Loper. 1987. Primary structure of the P450 lanosterol demethylase gene from Saccharomyces cerevisiae. DNA 6:529-537.
9. Kelly, S. L., D. C. Lamb, A. J. Corran, B. C. Baldwin, and D. E. Kelly. 1995. Mode of action and resistance to azole antifungals associated with the formation of 14α-methylergosta-8,24(28)-dien-3β,6α- diol. Biochem. Biophys. Res. Commun. 207:910-915.
10. Kelly, S. L., D. C. Lamb, C. J. Jackson, A. G. Warrilow, and D. E. Kelly. 2003. The biodiversity of microbial cytochromes P450. Adv. Microb. Physiol. 47:131-186.
11. Lamb, D. C., D. E. Kelly, B. C. Baldwin, and S. L. Kelly. 2000. Differential inhibition of human CYP3A4 and Candida albicans CYP51 with azole antifungal agents. Chem. Biol. Interact. 125:165-175.
12. Lamb, D. C., D. E. Kelly, M. R. Waterman, M. Stromstedt, D. Rozman, and S. L. Kelly. 1999. Characteristics of the heterologously expressed human lanosterol 14α-demethylase (other names: P45014DM, CYP51, P45051) and inhibition of the purified human and Candida albicans CYP51 with azole antifungal agents. Yeast 15:755-763.
13. Lepesheva, G. I., and M. R. Waterman. 2007. Sterol 14α-demethylase cytochrome P450 (CYP51), a P450 in all biological kingdoms. Biochim. Biophys. Acta 1770:467-477.
14. Lewis, J. H., H. J. Zimmerman, G. D. Benson, and K. G. Ishak. 1984. Hepatic injury associated with ketoconazole therapy. Analysis of 33 cases. Gastroenterology 86:503-513.
15. Löffler, J., S. L. Kelly, H. Hebart, U. Schumacher, C. Lass-Flörl, and H. Einsele. 1997. Molecular analysis of cyp51 from fluconazole-resistant Candida albicans strains. FEMS Microbiol. Lett. 151:263-268.
16. Maertens, J. A. 2004. History of the development of azole derivatives. Clin. Microbiol. Infect. 10 (Suppl. 1):1-10.
17. Marichal, P., J. Gorrens, L. Laurijssens, K. Vermuyten, C. Van Hove, L. Le Jeune, P. Verhasselt, D. Sanglard, M. Borgers, F. C. S. Ramaekers, F. Odds, and H. Vanden Bossche. 1999. Accumulation of 3-ketosteroids induced by itraconazole in azole-resistant clinical Candida albicans isolates. Antimicrob. Agents Chemother. 43:2663-2670.
18. Masubuchi, Y., and T. Horie. 2007. Toxicological significance of mechanism-based inactivation of cytochrome p450 enzymes by drugs. Crit. Rev. Toxicol. 37:389-412.
19. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard. M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
20. Pfaller, M. A., S. Messer, and R. N. Jones. 1997. Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae. Antimicrob. Agents Chemother. 41:233-235.
21. Pont, A., P. L. Williams, S. Azhar, R. E. Reitz, C. Bochra, E. R. Smith, and D. A. Stevens. 1982. Ketoconazole blocks testosterone synthesis. Arch. Intern. Med. 142:2137-2140.
22. Pont, A., P. L. Williams, D. S. Loose, D. Feldman, R. E. Reitz, C. Bochra, and D. A. Stevens. 1982. Ketoconazole blocks adrenal steroid synthesis. Ann. Intern. Med. 97:370-372.
23. Sanglard, D., F. Ischer, L. Koymans, and J. Bille. 1998. Amino acid substitutions in the cytochrome P-450 lanosterol 14α-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob. Agents Chemother. 42:241-253.
24. Scott, L. J., and D. Simpson. 2007. Voriconazole: a review of its use in the management of invasive fungal infections. Drugs 67:269-298.
25. Sharp, P. M., and W.-H. Li. 1987. The Codon Adaptation Index - a measure of directional synonymous codon usage bias, and its potential applications. Nucleic Acids Res. 15:1281-1295.
26. Shyadehi, A. Z., D. C. Lamb, S. L. Kelly, D. E. Kelly, W. H. Schunck, J. N. Wright, D. Corina, and M. Akhtar. 1996. The mechanism of the acyl-carbon bond cleavage reaction catalyzed by recombinant sterol 14α-demethylase of Candida albicans (other names are: lanosterol 14α-demethylase, P-45014DM, and CYP51). J. Biol. Chem. 271:12445-12450.
27. Trösken, E. R., M. Adamska, M. Arand, J. A. Zarn, C. Patten, W. Völkel, and W. K. Lutz. 2006. Comparison of lanosterol-14α- demethylase (CYP51) of human and Candida albicans for inhibition by different antifungal azoles. Toxicology 228:24-32.
28. Watson, P. F., M. E. Rose, S. W. Ellis, H. England, and S. L. Kelly. 1989. Defective sterol C5-6 desaturation and azole resistance: a new hypothesis for the mode of action of azole antifungals. Biochem. Biophys. Res. Commun. 164:1170-1175.
29. Zarn, J. A., B. J. Bruschweiler, and J. R. Schlatter. 2003. Azole fungicides affect mammalian steroidogenesis by inhibiting sterol 14α-demethylase and aromatase. Environ. Health Perspect. 111:255-261.